SCHEMBL23796489

SCHEMBL23796489

O=C(Nc1ccc(S(=O)(=O)O)c(O)c1)c1cc(O)c(C(=O)Nc2ccc(S(=O)(=O)O)c(O)c2)cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SNCA P37840 1/20 0.50
▸ KMT2A Q03164 4/20 0.45
▸ PKM P14618 1/20 0.45
▸ P2RX1 P51575 2/20 0.44
▸ P2RX4 Q99571 1/20 0.44
▸ P2RX7 Q99572 1/20 0.44
▸ ALOX15 P16050 3/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ POLB P06746 1/20 0.43
▸ TERT O14746 1/20 0.41
▸ TNNI3 P19429 1/20 0.41
▸ TNNT2 P45379 1/20 0.41
▸ TNNC1 P63316 1/20 0.41
▸ HKDC1 Q2TB90 1/20 0.41
▸ SRC P12931 1/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ SENP7 Q9BQF6 1/20 0.41
▸ SENP6 Q9GZR1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30031945 1.00 SNCA (0.50) SNCAKMT2APKMP2RX1P2RX4
SCHEMBL23796514 0.87 SNCA (0.50) SNCAKMT2APKMP2RX1P2RX4
SCHEMBL30032694 0.87 SNCA (0.50) SNCAKMT2APKMP2RX1P2RX4
SCHEMBL23796721 0.87 KMT2A (0.57) SNCAKMT2APKMMEN1POLB
SCHEMBL23796299 0.86 ENPP2 (0.44) SNCAKMT2APKMP2RX1P2RX4
SCHEMBL30031696 0.86 ENPP2 (0.44) SNCAKMT2APKMP2RX1P2RX4
SCHEMBL23796619 0.83 TIMP3 (0.51) KMT2AP2RX1MEN1NPC1RAB9A
SCHEMBL30031931 0.83 TIMP3 (0.51) KMT2AP2RX1MEN1NPC1RAB9A
SCHEMBL23796662 0.83 AKR1C3 (0.52) KMT2APKMP2RX1P2RX4P2RX7
SCHEMBL23796947 0.83 PKM (0.49) SNCAKMT2APKMP2RX1P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4118069-B1 PARA-HYDROQUINONE DERIVATIVES AS VEGF, TNF AND/OR IL INHIBITORS FOR THE TREATMENT OF NEUROINFLAMMATORY DISEASES OM PHARMA SA (CH) 2024-10-23 — — EP claimed
US-20230150951-A1 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS OM PHARMA SA (CH) 2023-05-18 — — US claimed
EP-4118069-A1 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS OM Pharma SA (CH) 2023-01-18 — — EP claimed
CN-115279730-A 2, 5-or 2, 6-disubstituted hydroquinone derivatives having at least one carboxyl, sulfo or amido group useful as medicaments OM药物公司 2022-11-01 — — CN claimed
WO-2021180655-A1 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS OM PHARMA SA (CH) 2021-09-16 — — WO claimed
EP-3878837-A1 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS OM Pharma SA (CH) 2021-09-15 — — EP claimed
EP-4118069-B1 PARA-HYDROQUINONE DERIVATIVES AS VEGF, TNF AND/OR IL INHIBITORS FOR THE TREATMENT OF NEUROINFLAMMATORY DISEASES OM PHARMA SA (CH) 2024-10-23 — — EP disclosed
EP-3878837-A1 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS OM Pharma SA (CH) 2021-09-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150951-A1 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS HRH4, NCOA4, HRH3 SNCA 1134/4885KMT2A 3173/4885PKM 4651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback